Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

on in managing their cholesterol levels.

"There is a lot of interest in PCSK9 as an exciting new target for the treatment of high cholesterol and having demonstrated that SPC5001 effectively lowers LDL or the 'bad' cholesterol in preclinical studies, we are quickly moving forward with plans to advance SPC5001 into clinical studies as a potential new treatment to help patients better manage the risks of cardiovascular diseases," said Henrik Orum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. "SPC5001 is a testament to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we discovered, optimized and advanced SPC5001 into preclinical development in just 18 months."

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

"In addition to advancing SPC5001 into drug development for the treatment of high cholesterol, we remain on track to begin Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the second half of this year," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "In our internal programs and partnered programs, the versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be critical in developing effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases."

SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in development, including its most advanced c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 Tauriga Sciences, Inc. (OTCQB: TAUG) ... with interests in the natural wellness sector and in ... that its products will be featured at the SEC ... 27 th Annual Growth Stock Conference on March ... 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... SAN FRANCISCO, Calif. , Feb. 26, 2015 /PRNewswire/ ... the treatment of cancer, today announced that Sean ... a corporate overview at the upcoming Cowen and Company ... Boston . Dr. McCarthy,s presentation will take ... About CytomX Therapeutics CytomX Therapeutics develops ...
(Date:2/25/2015)... Feb. 25, 2015 /CNW/ - Radient Technologies Inc. (TSX-V: RTI) ... financial results for the third quarter of its fiscal ... Management,s Discussion and Analysis, and the CEO & CFO ... December 31, 2014 are available on www.SEDAR.com ... Appointment The Corporation is also pleased to announce the ...
(Date:2/25/2015)... Market Publishers Ltd is happy to announce that ... have been recently uploaded to its catalogue. , ... . This research report provides wealth of qualitative and ... mortar industry as well as includes an all-round analysis ... It focuses on the main regions such as North ...
Breaking Biology Technology:SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 3New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 4
... Contributed by G.H. Goldman, R. Geremia, M. ... , ... transformation protocols call for the addition of , ... period of exposure to DNA. However, ...
... Maren Bell and Robert Mortimer, Human Genome Center, Division,of Cell ... , Introduction ... yeast artificial chromosomes (YACs) has traditionally , ... is complicated, often unreliable, and transformation ...
... Contributed by Elizabeth Eustis-Turf*, Kiu-Mei Wang , and Lawrence , ... University of Illinois, Urbana- Champaign, ... into eukaryotic cells permits the study of many , ... ability to insert a gene into a high percentage of ...
Cached Biology Technology:Transformation of Filamentous Fungi by High-Voltage Electroporation 2Transformation of Filamentous Fungi by High-Voltage Electroporation 3Transformation of Filamentous Fungi by High-Voltage Electroporation 4Transformation of Filamentous Fungi by High-Voltage Electroporation 5Transformation of Filamentous Fungi by High-Voltage Electroporation 6Transformation of Filamentous Fungi by High-Voltage Electroporation 7Transformation of Filamentous Fungi by High-Voltage Electroporation 8Electroporation of Yeast Artificial Chromosomes 2Electroporation of Yeast Artificial Chromosomes 3Electroporation of Yeast Artificial Chromosomes 4Electroporation of Primary Bone Marrow Cells 2Electroporation of Primary Bone Marrow Cells 3Electroporation of Primary Bone Marrow Cells 4
(Date:2/18/2015)... Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Boston, MA Tuesday, March 3, 2015 ... Investors Conference, Orlando, FL Wednesday, March ... Live Webcasts To access the live webcasts for these events, ...
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... Acute lung injury caused by cell death, high and ... excess fluid in the lungs (pulmonary edema), may be ... researchers at Yale School of Medicine report in the ... study, which was completed in the laboratory of senior ...
... A first-of-its kind analysis of fifty years of remotely sensed ... in the size and number of more than 10,000 ponds ... and published this week in the Journal of Geophysical Research, ... with recent climate warming in Alaska and may have profound ...
... agent completely prevented the development of bone tumors in ... study, providing early evidence that it could treat, or ... for a number of cancers when they start to ... D. Anderson Cancer Center reported in the journal Cancer ...
Cached Biology News:Key to acute lung injury lies in Ang2 protein 2Shrinking ponds signal warmer, dryer Alaska 2'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3
... solution for scheduling, performing and documenting ... pipettes and liquid handling devices. Collects ... Supports all gravimetric calibration protocols ... NCCLS and GLP requirements Includes ...
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... which belong to the transforming growth ... is a large group of extra-cellular ... of development, reproductive function and tumor ... bone morphogenetic proteins, growth differentiation factors, ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
Biology Products: